Innophore

Catalophore based drug design, repurposing and large-scale virtual screenings for novel therapeutics and better enzymes.

[Innophore @innophore]

You can watch the presentation here: https://t.co/hV2fJUipmi

[Innophore @innophore]

And we are live!
Watch our CEO, Christian C. Gruber, as he presents at the NVIDIA #GTC24. We’ve gathered in our office here in Graz to join the event online.

[NVIDIA Europe @NVIDIAEU]

Discover AI's impact on drug discovery with GPU-powered BioNeMo at #GTC24.

On Mar 20, at 10am CET, learn how NVIDIA and @innophore innovate protein design, analyze biomolecular data, and apply insights through case studies in therapeutic breakthroughs. https://t.co/AxV7e85bLU

[Innophore @innophore]

His talk with David Ruau (Head of Strategic Alliances, Drug Discovery AI, NVIDIA), focuses on "Leveraging #AI for Enzyme and Drug Discovery."
Join in to hear how Innophore’s technology can be utilized for #drugdiscovery and predicting side effects using our CavitOmiX platform.

[Innophore @innophore]

Our CEO, Christian Gruber, will be presenting at @NVIDIAGTC 2024 on Wednesday, March 20th from 10:00 AM to 10:50 AM CET (2:00 AM to 2:50 AM PDT).

https://t.co/rmcvFegaxD

#GTC2024

[Innophore @innophore]

Our COO, Bettina Nestl, will attend Bio-Europe Spring 2024 in Barcelona next week. Excited to connect and share insights on enzyme discovery, drug repurposing, and side-effect prediction! #BioEurope2024 #biotech #Biopharma #Innophore

[Daniel Andrés @DaniZaragozista]

Inspiring talks by A. Pritzel from @DeepMind and B. Nestl from @innophore about the potencial of AI in Biocatalysis #Biotrans2023 @HetBiocat

[Innophore @innophore]

You can watch the recorded GTC 2023 livestream here: https://t.co/aDDywOjUe8

[Innophore @innophore]

NVIDIA’s CEO Jensen Huang gave his keynote at @NVIDIAGTC 2023 conference, unveiling the latest advancements in generative AI, large language models, cloud computing, and more. We could not be more proud to be among the selected #NVIDIA #BioNeMo partners 🎉

[Innophore @innophore]

Behind the paper at @NaturePortfolio on designing variant-specific therapeutic SARS-CoV-2 decoys. The workflow features our #Catalophore™ Halos, deep #neuralnetworks and MD #simulations plus experimental validation.

Read the full post here: https://t.co/JL45Oopa4C

[Innophore @innophore]

This workflow combines our #Catalophore™ Halos with deep neural networks in conjunction with MD #simulations, validated in vitro and BSL3 neutralization assays. Reducing time-to-market for #biologics is critical, fast and efficient #leadoptimization is key for many future drugs.

[Innophore @innophore]

The year is off to an exciting start: Together with our partners @SignalChem, @awscloud, @acibGmbH, @MedUniGraz and @UniGraz we demonstrated the #AI pipeline to optimize variant-specific therapeutic SARS-CoV-2 ACE2 #decoys.

https://t.co/0PjOe8LOsc

[Innophore @innophore]

#Antiviral drugs are one of the first lines of defense in fighting viral diseases. But is there a link between antiviral drugs and the evolution of the virus? Let's find out and read our recent publication here ⬇️
https://t.co/uucOCpQEPc

#SARSCoV2 #mutations

[Folmer Fredslund @[email protected] @folfDK]

The innophore teams CavitOmiX for your #PyMol cavities
#StructuralBiology
@[email protected]
#proteinstructureandfunction
#enzymeengineering

https://t.co/Kt3Y5xJNTF

[Innophore @innophore]

Scientific publications often just report the hard facts, leaving out the story on what lead to the final findings. Take a look behind the scenes of one of our most recent publications and learn more about its creation in our blog post at @NaturePortfolio.
https://t.co/D7KjzIh4Zq

[Kleine Zeitung @kleinezeitung]

Grazer und Wiener Wissenschafter entwickeln eine Technologie, mit der sie die Mutation von Viren beobachten und voraussagen wollen. https://t.co/vX6yNr9KME

[Uni Graz/University of Graz @UniGraz]

Grazer ForscherInnen entwickeln Technologie zur präzisen Einschätzung der Gefährlichkeit von Virus-Varianten 🔗 https://t.co/JdDoqOAVM1 #weworkfortomorrow 📷 @innophore, @luminous_lab #acib

[Scientific Reports @SciReports]

Using a structural bioinformatics approach, researchers from @innophore, @UniGraz and @awscloud predict that Omicron spike receptor binding domain has a higher affinity to human ACE2 receptors, when compared to the wild type reference.
https://t.co/vzDHUctNEw

[Innophore @innophore]

Out latest publication in @SciReports is online! We are excited to share the details on how we use our Catalophore Halo technology to rapidly track changes in the RBD/hACE2 interface.
Enjoy the short video summary and visit https://t.co/yAzpqIwQwZ to read the full text. #COVID19

[Research Square Covid-19 Preprints @RS_COVID19]

Recent changes in the mutational dynamics of the SARS-CoV-2 main-protease substantiate the danger of emerging resistance to antiviral drugs. #covid https://t.co/s0qm4PQaAr